After 12 years at Danbury Hospital and 10 years at Bristol Myers Squibb in Connecticut, Robert Hindes, MD, continued his work leading innovative clinical trials at Pharmasset, Inc in New Jersey. Having completed a fellowship in infectious disease at Harvard Medical School, Robert Hindes, MD, currently serves as the chief medical officer of Trek Therapeutics, a company whose portfolio includes the antiviral drug VX-497.
Acquired from Vertex Pharmaceuticals, VX-497 is a broad-spectrum antiviral drug that has applications against the Ebola, Lassa, Junin, and Zika viruses. Zika is a mosquito-borne virus that can be especially harmful for pregnant women and unborn babies. The virus can also be spread by sexual activity regardless of whether symptoms are present.
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly